Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Has A Couple Of Controversies To Cover During Earnings Call

Apr 26 2019

• By Mandy Jackson

Quarterly resluts on typewriter close up — Lilly's Q1 earnings will be released 30 April

Related Content

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Apr 11 2019

Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential

Feb 07 2019

Industry's Drug Pricing Power Is Running On Fumes

Feb 07 2019

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Sep 21 2018

Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?

Jul 18 2018

Lift-Off For Lilly In Cancer Genetics With Loxo Buy

Jan 07 2019

Lartruvo Phase III Fail Rocks Lilly Oncology Plans

Jan 21 2019

Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results

Apr 19 2019

Same Drug, Two Versions And Prices, This Time For Lilly's Humalog

Mar 04 2019

Related Companies

Eli Lilly and Company

Pfizer Inc.

Loxo Oncology at Lilly

Additional Topics

Sales & Earnings Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window